A Latin American consensus on the use of L-asparaginase in pediatric and adolescent/young adult acute lymphoblastic leukemia – part 1

Background L-asparaginase remains a fundamental component of curative therapy for children, adolescents and young adults (AYA; 15–39 years) with acute lymphoblastic leukemia (ALL). However, optimal treatment remains challenging across Latin America due to shortages, heterogeneous product quality, limited access to therapeutic drug monitoring (TDM), and toxicities. This study aimed to develop regionally adapted, evidence-informed recommendations for L-asparaginase use in ALL. Methods A multinational modified Delphi process involved 19 experts from 10 Latin American countries. Following a literature review, candidate statements were developed. Consensus was predefined as ≥80% of respondents assigning scores of 7–9 on a 9-point Likert scale. Statements not reaching consensus underwent iterative discussion, revision, and reevaluation. Results Ninety-three statements were evaluated in the first anonymous voting round and grouped post hoc into five thematic blocks; this first part reports the 46 statements of blocks 1–3: treatment continuity, pharmacokinetic and dosing principles, and TDM and treatment optimization. Round-level participation was 94.7%, 84.2%, and 84.2% in Rounds 1–3. Thirty-two statements achieved consensus in the first round. The 14 that did not were subdivided, merged, reformulated, or withdrawn, yielding 14 revised statements; six achieved consensus in the second round, one was withdrawn, and the remaining seven were consolidated into six third-round statements, all achieving consensus. The process resulted in 44 final consensus statements. Key recommendations emphasize preservation of therapeutic exposure, avoidance of unnecessary discontinuation, formulation-specific pharmacokinetics and dosing, linkage of dose and dosing intervals to the desired duration of exposure, and expansion of TDM, with serum asparaginase activity ≥0.1 IU/mL at a formulation- and schedule-appropriate sampling time endorsed as the minimum therapeutic target. Conclusions This consensus provides a multinational Latin American framework for L-asparaginase use in ALL. The recommendations support exposure-centered treatment strategies and identify priorities for regional collaboration, including pharmacokinetic monitoring, toxicity management, and access to high-quality L-asparaginases.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-12
DOI
https://doi.org/10.3389/fonc.2026.1984411
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Latin American consensus on the use of L-asparaginase in pediatric and adolescent/young adult acute lymphoblastic leukemia – part 1

Mecneide Mendes Lins, Scott C. Howard, María de los Angeles del Campo Martínez, Hugo Antonio Romo-Rubio et al.
Frontiers in Oncology
Acute Lymphoblastic Leukemia research
article

A Latin American consensus on the use of L-asparaginase in pediatric and adolescent/young adult acute lymphoblastic leukemia – part 1

Mecneide Mendes Lins, Scott C. Howard, María de los Angeles del Campo Martínez, Hugo Antonio Romo-Rubio, Benilda González, Marcelo Gerardin Poirot Land, Gabriela Abigail Villanueva, Oscar González‐Ramella, Roberta Demichelis‐Gómez, Roberto Vásquez, Jeanine Alfaro, Carlos E. Narváez, María Sara Felice, Alberto Olaya Vargas, Irene Medina Castillo, Sharon Chávez Paredes, Diego Daniel Figueredo González, Cesar A. Galvan Diaz
article en

Abstract

Background L-asparaginase remains a fundamental component of curative therapy for children, adolescents and young adults (AYA; 15–39 years) with acute lymphoblastic leukemia (ALL). However, optimal treatment remains challenging across Latin America due to shortages, heterogeneous product quality, limited access to therapeutic drug monitoring (TDM), and toxicities. This study aimed to develop regionally adapted, evidence-informed recommendations for L-asparaginase use in ALL. Methods A multinational modified Delphi process involved 19 experts from 10 Latin American countries. Following a literature review, candidate statements were developed. Consensus was predefined as ≥80% of respondents assigning scores of 7–9 on a 9-point Likert scale. Statements not reaching consensus underwent iterative discussion, revision, and reevaluation. Results Ninety-three statements were evaluated in the first anonymous voting round and grouped post hoc into five thematic blocks; this first part reports the 46 statements of blocks 1–3: treatment continuity, pharmacokinetic and dosing principles, and TDM and treatment optimization. Round-level participation was 94.7%, 84.2%, and 84.2% in Rounds 1–3. Thirty-two statements achieved consensus in the first round. The 14 that did not were subdivided, merged, reformulated, or withdrawn, yielding 14 revised statements; six achieved consensus in the second round, one was withdrawn, and the remaining seven were consolidated into six third-round statements, all achieving consensus. The process resulted in 44 final consensus statements. Key recommendations emphasize preservation of therapeutic exposure, avoidance of unnecessary discontinuation, formulation-specific pharmacokinetics and dosing, linkage of dose and dosing intervals to the desired duration of exposure, and expansion of TDM, with serum asparaginase activity ≥0.1 IU/mL at a formulation- and schedule-appropriate sampling time endorsed as the minimum therapeutic target. Conclusions This consensus provides a multinational Latin American framework for L-asparaginase use in ALL. The recommendations support exposure-centered treatment strategies and identify priorities for regional collaboration, including pharmacokinetic monitoring, toxicity management, and access to high-quality L-asparaginases.

Frontiers in OncologyVol. 16
Universidade Federal do Rio de Janeiro (BR), Hospital Sant Joan de Déu Barcelona (ES), Mexican Social Security Institute (MX), Universidad de Guadalajara (MX), Garrahan Hospital (AR), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX), Instituto de Medicina Integral Professor Fernando Figueira (BR), Hospital Nacional de Niños Bloom (SV), Hospital de Clínicas "José de San Martín" (AR), Hospital Civil de Guadalajara (MX), Instituto Nacional de Enfermedades Neoplásicas (PE), Instituto Nacional de Pediatria (MX), Hospital del Niño (PA), Resonance (United States) (US), Sociedad de Lucha Contra el Cáncer del Ecuador (EC), Universidad Nacional de Asunción (PY), Universidad del Valle (CO)
Good health and well-being
Acute Lymphoblastic Leukemia research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon